Why Denial Taxonomy Matters
When a prior authorization or claim comes back denied, the worst thing a revenue cycle team can do is launch a generic appeal. Payers process thousands of appeals; a letter that doesn't directly address the denial reason reads as noise and fails at a high rate.
The first step in every denial workflow should be the same: identify the specific denial reason code and the policy basis the payer cited. That information tells you exactly what argument you need to make, which documentation to gather, and which escalation pathway to pursue. This article maps the most common denial categories for genetic testing and oncology and provides a practical escalation guide for each.
Category 1: Medical Necessity Denial
What it means: The payer's reviewer determined that the submitted clinical information did not satisfy the coverage criteria for the requested service. This is the most common denial type in genetic testing and oncology, and it is also the most frequently overturned on appeal.
Why it happens: Medical necessity denials often reflect documentation gaps rather than a genuine lack of clinical appropriateness. The ordering provider's notes may support the service clearly, but if the PA submission did not include the right ICD-10 code combination, the treating physician's specific clinical reasoning, or the applicable guideline reference (e.g., NCCN category designation), the reviewer cannot make the connection.
Escalation pathway:
- Request a peer-to-peer review immediately. Most payers allow 5–14 business days post-denial. A physician-to-physician conversation is the highest-yield intervention for medical necessity denials. The ordering physician should be prepared to walk through the clinical rationale, guideline support, and why alternatives are inappropriate.
- First-level administrative appeal: If peer-to-peer fails or is unavailable, submit a formal appeal with enhanced documentation — a detailed letter of medical necessity from the treating physician, the specific NCCN guideline page with the applicable category designation, and any relevant peer-reviewed literature.
- External review: If internal appeals are exhausted, request an independent external review under state or federal law. Independent reviewers approve at materially higher rates than payer internal reviewers for oncology services.
Category 2: Missing or Insufficient Documentation
What it means: The payer received the request but indicated that required supporting documentation was absent or incomplete. This is technically a "pend" or "hold" rather than a true denial, but it functions like one if the deadline to respond is missed.
Why it happens: Payers publish specific documentation checklists in their PA guidelines that differ by service. For genetic testing, common missing elements include: ordering provider NPI, treating diagnosis with supporting clinical notes, prior testing results (especially for reflex or companion testing), family history documentation, and — for MolDX-managed tests — the DEX Z-code.
Escalation pathway:
- Respond within the payer's stated timeframe — typically 10–14 business days. Missing this window converts a pend to a denial with stricter appeal rights.
- Submit the complete documentation package, not just the missing item. Payers often identify only one gap in the initial request; a complete resubmission prevents another round-trip.
- If denied due to missed deadline, appeal on procedural grounds and simultaneously resubmit as a new PA request if clinically timely.
Category 3: Non-Covered Service
What it means: The payer determined that the requested service is simply not a covered benefit under the patient's plan — regardless of medical necessity.
Why it happens: Benefit exclusions are common for certain categories of genetic testing, particularly when laboratory-developed tests (LDTs) are not included in a payer's contracted test menu, or when a molecular test has not yet been added to the payer's covered services list.
Escalation pathway:
- Verify the denial is truly a benefit exclusion and not a miscoded medical policy denial. Request the specific contract language or benefit document the payer relied on.
- Check for exceptions: Some plans exclude genetic testing categorically but include exceptions for companion diagnostics required by FDA-approved therapies or for NCCN Category 1 indications.
- File a coverage determination request: If you believe the service should be covered based on parity laws, state mandates, or the ACA's preventive care provisions, file a formal coverage determination challenge.
- Patient assistance pathway: If the service is genuinely excluded and the patient has a compelling clinical need, engage the treating physician to explore manufacturer patient assistance programs.
Category 4: Prior Authorization Not Obtained
What it means: The service was delivered before PA was obtained, and the payer is denying the claim on that basis. This is a process failure, not a clinical one.
Why it happens: Emergency or urgent clinical situations, rapid turnaround requirements for time-sensitive oncology decisions, or breakdowns in the PA workflow between the ordering provider and the lab.
Escalation pathway:
- Retro-authorization: Many payers accept retroactive PA requests for services rendered in emergent or urgent circumstances. Submit within the payer's retro-auth window (often 24–72 hours post-service for emergencies; some allow up to 30 days).
- Document the clinical urgency: The appeal should explain why obtaining PA prior to service delivery was clinically not feasible — for example, a biopsy result that necessitated immediate next-generation sequencing to guide treatment decisions with a narrow window.
- Review the provider agreement: Some provider contracts limit or waive PA requirements for certain service types. Confirm whether the denial has any contractual basis.
Category 5: Experimental or Investigational
What it means: The payer classified the requested service as experimental or investigational (E&I), meaning it does not yet meet their evidentiary standards for coverage.
Why it happens: This denial is particularly common for novel biomarker assays, laboratory-developed tests, and emerging companion diagnostics. Payers typically require FDA approval, consistent peer-reviewed evidence, and often MolDX or NCCN endorsement before reclassifying a test from investigational to covered.
Escalation pathway:
- Build the evidentiary case: Compile peer-reviewed publications demonstrating clinical utility (not just analytical validity), FDA clearance or approval documentation, NCCN guideline listings, and any positive coverage determinations from other payers or CMS.
- Challenge the classification: If the test has FDA approval and NCCN Category 1 or 2A designation, the E&I classification is often legally challengeable. File an appeal citing these authorities directly.
- Clinical trial coverage: If the patient is enrolled in a clinical trial, the ACA mandates coverage of routine costs for qualifying trials. File under this provision if applicable.
- Medical necessity + E&I combination appeal: Some payers will approve a service under E&I exception criteria when standard therapy has failed and no covered alternative exists. Frame the appeal around treatment necessity and lack of alternatives.
Category 6: Duplicate Claim or Service
What it means: The payer flagged the claim as a duplicate of a previously processed claim or of a service delivered within a defined service frequency period.
Why it happens: Molecular testing can trigger this denial when a reflex or reflexed-to test uses the same CPT code family as a prior test, or when billing for a panel and individual components occurs simultaneously.
Escalation pathway:
- Review for coding errors: Confirm the claim was not a true duplicate. If it was, correct and resubmit.
- Document clinical distinction: If the new test is clinically distinct (e.g., a somatic panel following a germline test, or a repeat test after a clinically significant interval), the appeal should clearly articulate the clinical differentiation and cite the specific policy basis that permits repeat testing.
Category 7: Benefit Coordination / Other Insurance Primary
What it means: The payer is indicating that another insurer is primary and should be billed first.
Escalation pathway: Verify COB (coordination of benefits) information with the patient. Bill the correct primary payer first, then submit the secondary claim with the EOB from the primary payer attached.
Building a Denial Management Program
Effective denial management is a system, not a firefighting exercise. At a minimum, your team should:
- Track denial reasons by category, payer, and test type to identify patterns
- Establish time-sensitive peer-to-peer request triggers (within 48 hours of medical necessity denial)
- Maintain a library of clinical literature and guideline citations indexed by test and indication
- Monitor appeal overturn rates by denial type and payer to prioritize effort
The data consistently shows that 60–70% of prior authorization denials that go to appeal are overturned. The bottleneck is not the outcome — it is the bandwidth and process to pursue them systematically.